Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Washington

CNS medication trials in Washington

63 CNS medication studies are recruiting participants at sites in 7 cities across Washington as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Washington by city

Cities with the most studies recruiting right now.

Every Washington city with a recruiting study

By research area: Depression (24), Schizophrenia (10), Parkinson's Disease (9), Multiple Sclerosis (6), ADHD (5), Migraine (5), Epilepsy (3), Bipolar Disorder (1).

Bellevue (26), Seattle (23), Everett (16), Spokane (7), Kirkland (4), Tacoma (2), Silverdale (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in Washington

Basic details from each study's public record (the 12 most recently updated of 63). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Recruiting in
    Everett
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Recruiting in
    Seattle
    Registry record
    NCT06793397 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Recruiting in
    Seattle
    Registry record
    NCT07002034 · updated
  4. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Recruiting in
    Everett
    Registry record
    NCT07065240 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Washington on ClinicalTrials.gov.

Schizophrenia: recently updated in Washington

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Recruiting in
    Bellevue
    Registry record
    NCT06887192 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Washington on ClinicalTrials.gov.

ADHD: recently updated in Washington

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Recruiting in
    Everett
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Recruiting in
    Everett
    Registry record
    NCT07717892 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Washington on ClinicalTrials.gov.

Parkinson's disease: recently updated in Washington

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Seattle · Silverdale
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Seattle
    Registry record
    NCT06841354 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Seattle · Spokane · Tacoma
    Registry record
    NCT06966700 · updated
  4. SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

    • Phase 1
    • Ages 40 to 80
    • All sexes
    Sponsor
    Serina Therapeutics
    Recruiting in
    Spokane
    Registry record
    NCT07422675 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Washington on ClinicalTrials.gov.

Multiple sclerosis (MS): recently updated in Washington

  1. Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

    • Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    Kite, A Gilead Company
    Recruiting in
    Seattle
    Registry record
    NCT07304154 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Washington on ClinicalTrials.gov.

Ask about studies in Washington

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call